Prediabetes Annual Evaluation Checklist: What to Test, When, and Why

What Exactly Is Prediabetes and Who Needs Annual Follow-Up?

Prediabetes is a confirmed dysglycemic state sitting between normal glucose regulation and type 2 diabetes. The American Diabetes Association defines it by any one of three criteria: fasting plasma glucose 100 to 125 mg/dL, A1c 5.7 to 6.4%, or a 2-hour plasma glucose of 140 to 199 mg/dL during a 75-gram oral glucose tolerance test (OGTT) [1]. Any adult meeting one of those criteria needs structured annual follow-up, not just a note in the chart.

Who Carries the Highest Conversion Risk?

The risk of progression is not uniform. Individuals with A1c at the upper end of the prediabetes range (6.0 to 6.4%) carry roughly twice the 5-year conversion risk compared with those near 5.7% [2]. Additional risk amplifiers include a body mass index at or above 35 kg/m², first-degree family history of type 2 diabetes, gestational diabetes history, polycystic ovary syndrome, and non-alcoholic fatty liver disease.

The USPSTF recommends screening for prediabetes and type 2 diabetes in adults aged 35 to 70 who have overweight or obesity, with grade B evidence [3]. That same population needs annual re-evaluation once prediabetes is identified.

Why Annual (Not Biennial) Monitoring?

The Diabetes Prevention Program (DPP, N=3,234) showed that without intervention, 11% of placebo-group participants converted to type 2 diabetes per year [4]. Annual lab review catches accelerating progression early, before permanent beta-cell dysfunction accumulates. The ADA 2025 Standards of Care state that "patients with prediabetes should be tested every one to two years" to detect conversion, but clinical practice guidelines at most major health systems default to annual testing for the highest-risk subset [1].

The Core Annual Lab Panel for Prediabetes

Getting the right tests at the right interval is the backbone of prediabetes management. The table below maps each test to its clinical purpose and the guideline that recommends it.

Glycemic Status Tests

A1c or Fasting Plasma Glucose. These are the two most practical glycemic surveillance tools. A1c reflects average glucose over roughly 90 days and does not require fasting. Fasting plasma glucose captures the hepatic overnight glucose output that typically rises first as insulin resistance worsens. The ADA recommends using either test annually in confirmed prediabetes [1]. Repeating both during the same visit is reasonable when A1c and fasting glucose gave discordant results at diagnosis.

Oral Glucose Tolerance Test (OGTT). Not required every year, but worth repeating every 2 to 3 years in patients whose A1c and fasting glucose remain discordant or whose post-meal symptoms suggest impaired glucose tolerance not captured by fasting tests alone [1].

Cardiometabolic and Organ-Protection Labs

Fasting Lipid Panel. People with prediabetes carry elevated rates of dyslipidemia, particularly elevated triglycerides and low HDL-cholesterol, even before the A1c crosses into the diabetic range. The ADA recommends a fasting lipid panel at least annually to guide statin therapy decisions [1]. The ACC/AHA Pooled Cohort Equation uses this data to calculate 10-year atherosclerotic cardiovascular disease (ASCVD) risk, which then informs whether a statin is warranted [5].

Urine Albumin-to-Creatinine Ratio (uACR) and eGFR. Microalbuminuria can precede a formal type 2 diabetes diagnosis. Annual uACR screening allows detection of early nephropathy at a stage when intervention, primarily renin-angiotensin system blockade, is most effective [1]. A uACR above 30 mg/g or an eGFR below 60 mL/min/1.73 m² on a single reading warrants repeat confirmation within 3 months.

ALT (Alanine Aminotransferase). Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) affects roughly 55 to 70% of adults with prediabetes [6]. An elevated ALT is the simplest first-pass screen. The ADA and the American Association for the Study of Liver Diseases recommend checking liver enzymes in patients with prediabetes plus central obesity or triglycerides above 150 mg/dL [1].

Thyroid-Stimulating Hormone (TSH). Hypothyroidism worsens insulin resistance and raises LDL-cholesterol. The ADA does not mandate annual TSH in all prediabetes patients, but the American Association of Clinical Endocrinology (AACE) recommends it in women over 50 and in anyone with symptoms or a prior thyroid disorder [7]. Check it at baseline and then repeat every 1 to 2 years if the clinical picture warrants.

Blood Pressure, Weight, and Waist Circumference: The Vital Signs That Drive Risk

Lab values tell only part of the story. Three measured clinical parameters at every annual visit carry equal prognostic weight.

Blood Pressure

The ADA 2025 Standards set a blood pressure target of below 130/80 mmHg for adults with prediabetes and any additional cardiovascular risk factor [1]. Hypertension and prediabetes coexist in about 40% of affected adults, and the combination accelerates both renal and cardiac risk. At the annual visit, two seated readings taken at least 1 minute apart should be averaged and documented.

Body Weight and Waist Circumference

A 5 to 7% reduction in body weight is the specific threshold the DPP lifestyle intervention used to demonstrate a 58% reduction in diabetes incidence [4]. That translates to roughly 10 to 14 lbs for a 200-lb individual. Waist circumference adds information that BMI alone misses: visceral fat is metabolically active in a way that subcutaneous fat is not. The ADA defines elevated waist circumference as above 40 inches (102 cm) in men and above 35 inches (88 cm) in women, with lower thresholds for Asian adults [1].

At the annual visit, document both BMI and waist circumference. Progress toward the 5 to 7% weight-loss target should be assessed explicitly, not assumed.

Physical Activity Self-Report

The DPP lifestyle arm targeted 150 minutes of moderate-intensity physical activity per week. Asking a structured question at each annual visit, "How many minutes of brisk walking or equivalent activity did you complete per week on average over the past 3 months?" captures adherence more accurately than a generic "are you exercising?" [4].

Medication Review: When to Start, Adjust, or Stop Pharmacotherapy

Deciding Whether Metformin Is Indicated

Metformin is the only medication with ADA guideline support for prediabetes pharmacotherapy outside of a clinical trial. The 2025 ADA Standards state: "Metformin therapy for prevention of type 2 diabetes should be considered in those with prediabetes, especially for those with BMI <35 kg/m² who are aged 25 to 59 years with fasting plasma glucose 110 to 125 mg/dL or A1c 6.0 to 6.4%, and for women with history of gestational diabetes." [1]

The DPP showed metformin 850 mg twice daily reduced conversion by 31% compared to placebo over 2.8 years [4]. The DPP Outcomes Study (DPPOS), a 15-year follow-up of the same cohort, confirmed that metformin users maintained a sustained 18% reduction in diabetes incidence relative to placebo even when lifestyle adherence declined [8].

At each annual visit, if metformin was started, review:

• Current dose (target 1,000 mg twice daily with meals once tolerated)
• GI tolerability (diarrhea, nausea) and whether extended-release formulation was offered
• Vitamin B12 level (metformin can reduce B12 absorption with long-term use; ADA recommends periodic monitoring) [1]
• eGFR to confirm safety (dose reduction needed below 45 mL/min/1.73 m², contraindicated below 30 mL/min/1.73 m²)

GLP-1 Receptor Agonists and Other Agents

Semaglutide and liraglutide are not FDA-approved specifically for prediabetes prevention, but data from obesity trials are relevant. In STEP-1 (N=1,961), semaglutide 2.4 mg subcutaneous weekly produced 14.9% mean weight loss at 68 weeks versus 2.4% in the placebo group (P<0.001) [9]. At that magnitude of weight loss, conversion from prediabetes to normoglycemia is probable for a large fraction of treated patients, though the STEP program was not powered specifically to measure that endpoint.

Pioglitazone and acarbose have trial-level evidence for prediabetes, but both carry side-effect profiles (weight gain and fluid retention for pioglitazone; GI intolerance for acarbose) that limit routine use. The ACT NOW trial (N=602) showed pioglitazone 45 mg/day reduced conversion to type 2 diabetes by 72% versus placebo over a median of 2.4 years, but participants gained a mean of 3.9 kg [10].

Reviewing Medications That Worsen Glycemia

Several drug classes raise blood glucose and should be reviewed at every annual visit in patients with prediabetes:

• Corticosteroids (systemic, including inhaled high-dose)
• Thiazide diuretics at doses above 12.5 to 25 mg/day
• Atypical antipsychotics (olanzapine, quetiapine, clozapine)
• Immunosuppressants (tacrolimus, cyclosporine)

If any of these are ongoing, consider whether an alternative is appropriate, or factor the pharmacological contribution into the glycemic trend interpretation.

Lifestyle Intervention Progress: Structured Assessment at Each Annual Visit

The Diabetes Prevention Program demonstrated that structured lifestyle change outperforms medication as a first-line strategy. A 58% reduction in incidence versus 31% for metformin, from the same trial and the same follow-up period, is a margin that justifies a thorough annual lifestyle review [4].

Diet Quality Assessment

Rather than a generic dietary recall, the annual visit should screen for three specific dietary patterns associated with prediabetes progression:

1. Sugar-sweetened beverage intake above 1 serving per day (each daily serving associated with an approximately 18% higher type 2 diabetes risk in meta-analyses covering over 310,000 participants) [11]
2. Refined carbohydrate load (white bread, white rice, and processed snacks) at more than half of total grain intake
3. Saturated fat intake as a surrogate marker for red and processed meat consumption

These questions take under 3 minutes using validated tools like the Rapid Eating Assessment for Patients (REAP-S) or a single-page ADA diet screen.

Exercise and Activity

150 minutes of moderate-intensity aerobic exercise per week is the ADA-recommended minimum for adults with prediabetes [1]. Resistance training 2 to 3 times per week adds independent glycemic benefit: a 2010 JAMA-published trial (N=251) found that combined aerobic plus resistance training reduced A1c by 0.34 percentage points more than aerobic exercise alone over 22 weeks [12].

At the annual visit, document minutes per week and note whether any supervised program, such as a CDC-recognized Diabetes Prevention Program lifestyle change program, is in place or has been referred to.

Sleep and Stress

Sleep duration below 6 hours per night is associated with a 28% higher risk of incident diabetes in meta-analyses [13]. Obstructive sleep apnea, which is common in patients with obesity and prediabetes, independently impairs insulin sensitivity. Screening with the STOP-BANG questionnaire takes under 2 minutes at the annual visit and generates a referral threshold for polysomnography.

Referral Decisions and Care Coordination at the Annual Visit

Not every prediabetes patient needs specialist care, but certain annual findings should trigger referral.

When to Refer to Endocrinology

• A1c crosses 6.5% or fasting glucose exceeds 125 mg/dL on two separate tests: this meets ADA criteria for type 2 diabetes and requires formal diagnosis and treatment initiation [1]
• Uncontrolled blood pressure above 160/100 mmHg despite two antihypertensives
• eGFR below 45 mL/min/1.73 m² or uACR above 300 mg/g

When to Refer to a Registered Dietitian

The ADA recommends medical nutrition therapy (MNT) delivered by a registered dietitian nutritionist as a covered Medicare benefit for patients with prediabetes and at least one additional metabolic risk factor [1]. An annual visit finding of persistent A1c above 6.0% despite lifestyle effort is a clear referral trigger.

Diabetes Prevention Program Enrollment

The CDC-recognized National DPP lifestyle change program is available in-person and virtually throughout the United States. The ADA 2025 Standards explicitly recommend referral to a DPP-recognized program for all patients with prediabetes [1]. Completion of the full 12-month program is associated with an average 5% body weight reduction and a roughly 40 to 70% reduction in diabetes incidence in real-world implementation studies [14].

Putting the Checklist Together: A One-Page Annual Visit Framework

Every annual prediabetes evaluation should cover the following items before the patient leaves:

Glycemic status

• A1c (fasting not required) or fasting plasma glucose
• Document trend versus prior year value

Cardiometabolic labs

• Fasting lipid panel (total cholesterol, LDL, HDL, triglycerides)
• uACR (spot urine) and serum creatinine with eGFR
• ALT
• TSH if indicated by age, sex, or symptoms

Metabolic monitoring for patients on metformin

• Serum vitamin B12 (every 2 to 3 years once stable on metformin per ADA)
• eGFR confirmation for dosing safety

Vital signs and anthropometrics

• Blood pressure (average of two readings)
• BMI and body weight with year-over-year change
• Waist circumference

Lifestyle review

• Minutes of moderate activity per week (target: 150 or more)
• Dietary pattern screen (sugar-sweetened beverages, refined carbohydrates)
• STOP-BANG sleep apnea screen if BMI is 30 or above
• Tobacco and alcohol use

Medication review

• Confirm metformin dose and tolerability if prescribed
• Screen for glycemia-worsening medications
• Document whether GLP-1 therapy or bariatric surgery has been discussed for BMI above 35

Referrals and programs

• CDC-recognized National DPP enrollment status
• Registered dietitian referral if A1c is above 6.0% without dietary counseling in the prior year
• Endocrinology if A1c has crossed 6.5% or fasting glucose exceeds 125 mg/dL on two tests